|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
US7112324B1
(en)
|
1998-04-21 |
2006-09-26 |
Micromet Ag |
CD 19×CD3 specific polypeptides and uses thereof
|
|
ES2248127T3
(es)
|
1999-10-04 |
2006-03-16 |
Medicago Inc. |
Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
US9770517B2
(en)
*
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
DE10231109A1
(de)
|
2002-07-10 |
2004-01-22 |
Daimlerchrysler Ag |
Abgasturbine
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
|
JP2008501621A
(ja)
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
MXPA06004035A
(es)
|
2003-10-16 |
2006-08-31 |
Micromet Ag |
Aglutinantes cd3 de-inmunizados multi-especificos.
|
|
US20090252681A1
(en)
|
2005-10-11 |
2009-10-08 |
Ablynx N.V. |
Nanobodies and Polypeptides Against EGFR and IGF-IR
|
|
WO2007042289A2
(en)
|
2005-10-11 |
2007-04-19 |
Ablynx N.V. |
Nanobodies™ and polypeptides against egfr and igf-ir
|
|
RU2008129827A
(ru)
|
2005-12-21 |
2010-01-27 |
МЕДИММЬЮН, ЭлЭлСи (US) |
МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
|
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
WO2008091798A2
(en)
*
|
2007-01-22 |
2008-07-31 |
Xencor, Inc. |
Optimized ca9 antibodies and methods of using the same
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
AR076508A1
(es)
|
2009-05-01 |
2011-06-15 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
SG10201405434VA
(en)
|
2009-09-18 |
2014-10-30 |
Amgen Res Munich Gmbh |
Dosage regimen for administering an epcamxcd3 bispecific antibody
|
|
EA201500220A1
(ru)
*
|
2010-05-17 |
2015-10-30 |
Ливтех, Инк. |
Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
|
|
EP2571901B1
(en)
|
2010-05-20 |
2019-01-02 |
Ablynx N.V. |
Biological materials related to her3
|
|
CN103068847B
(zh)
|
2010-08-24 |
2019-05-07 |
罗切格利卡特公司 |
可活化的双特异性抗体
|
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
KR102060389B1
(ko)
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
|
RU2014103288A
(ru)
|
2011-07-01 |
2015-08-10 |
Байер Интеллектчуал Проперти Гмбх |
Слитые полипептиды релаксина и их применение
|
|
PE20141522A1
(es)
|
2011-08-17 |
2014-11-17 |
Glaxo Group Ltd |
Proteinas y peptidos modificados
|
|
UY34504A
(es)
|
2011-12-09 |
2013-06-28 |
Amgen Res Munich Gmbh |
Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3
|
|
CA2861003C
(en)
|
2012-01-13 |
2023-03-28 |
Julius-Maximilians-Universitat Wurzburg |
Dual antigen-induced bipartite functional complementation
|
|
PH12021553014A1
(en)
|
2012-02-27 |
2022-09-05 |
Ablynx Nv |
Cx3cr1-binding polypeptides
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
MX353382B
(es)
|
2012-03-01 |
2018-01-10 |
Amgen Res Munich Gmbh |
Moleculas de union polipeptido de larga duracion.
|
|
CN110078827A
(zh)
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
AU2013258834B2
(en)
*
|
2012-05-10 |
2017-09-07 |
Zymeworks Bc Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
|
EP2863948B1
(en)
|
2012-06-22 |
2018-10-24 |
Cytomx Therapeutics Inc. |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
US9382329B2
(en)
*
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
KR20160018579A
(ko)
|
2013-06-04 |
2016-02-17 |
싸이톰스 테라퓨틱스, 인크. |
활성화가능 항체를 접합하기 위한 조성물 및 방법
|
|
CA3051222C
(en)
|
2013-06-10 |
2023-01-24 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for reducing immunosupression by tumor cells
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
CA2942245C
(en)
*
|
2014-03-12 |
2021-11-02 |
Yeda Research And Development Co. Ltd. |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
EP3699195A3
(en)
|
2014-03-28 |
2020-11-04 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
KR102485788B1
(ko)
|
2014-08-27 |
2023-01-09 |
메모리얼 슬로안 케터링 캔서 센터 |
항체, 조성물 및 용도
|
|
DK4074735T3
(da)
|
2014-08-28 |
2025-07-14 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
MX2017003847A
(es)
|
2014-09-25 |
2017-12-15 |
Amgen Inc |
Proteinas biespecificas activables por proteasas.
|
|
ES3029413T3
(en)
|
2015-04-02 |
2025-06-24 |
Ablynx Nv |
Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
|
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
IL292798A
(en)
|
2015-05-04 |
2022-07-01 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
|
|
LT3611192T
(lt)
|
2015-05-13 |
2025-06-25 |
Ablynx N.V. |
T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
FI3377103T4
(fi)
|
2015-11-19 |
2025-04-16 |
Revitope Limited |
Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
|
|
CN109071667A
(zh)
|
2016-03-08 |
2018-12-21 |
马弗里克治疗公司 |
可诱导性结合蛋白和使用方法
|
|
WO2017201493A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
US20190225702A1
(en)
|
2016-10-14 |
2019-07-25 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
|
US11535668B2
(en)
*
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018160671A1
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Targeted checkpoint inhibitors and methods of use
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
CN111315773A
(zh)
|
2017-09-08 |
2020-06-19 |
马弗里克治疗公司 |
含有Fc区的条件性活化的结合部分
|
|
CN108484771A
(zh)
*
|
2018-04-24 |
2018-09-04 |
南京市妇幼保健院 |
EpCAM单域抗体G7
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
WO2019222278A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Dual binding moiety
|
|
WO2019222282A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Conditionally activated binding protein comprising a sterically occluded target binding domain
|
|
CN113286811B
(zh)
|
2018-07-30 |
2024-12-06 |
南加利福尼亚大学 |
改善过继性细胞疗法的效力和安全性
|
|
US20210309756A1
(en)
|
2018-08-09 |
2021-10-07 |
Maverick Therapeutics, Inc. |
Coexpression and purification method of conditionally activated binding proteins
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3897851A2
(en)
|
2018-12-17 |
2021-10-27 |
Revitope Limited |
Twin immune cell engager
|
|
EP3897719A4
(en)
|
2018-12-21 |
2022-11-02 |
Zhejiang Shimai Pharmaceutical Co., Ltd. |
Protease cleavable bispecific antibodies and uses thereof
|
|
JP2022524337A
(ja)
|
2019-03-05 |
2022-05-02 |
武田薬品工業株式会社 |
腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
AU2020267131A1
(en)
|
2019-05-02 |
2021-11-25 |
Revitope Limited |
TEAC and ATTAC immunooncology compositions and methods
|